# The Author(s) 2012. This article is published with open access at Springerlink.com Abstract The late Na current is of pathophysiological im-portance for the heart. Ranolazine is an innovative anti-ischemic and antianginal agent that inhibits the late Na current, thereby reducing the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia. In addition, ranolazine seems to exert beneficial effects on diastolic cardiac function. Moreover, there are experimental and clinical data about its antiarrhyth-mic properties. A beneficial atrial selectivity of ranolazine has been suggested that may be helpful for the treatment of atrial fibrillation. The purpose of this review article is to discuss possib...
Ranolazine derives from piperazine and has been approved as a drug for the therapy of chronic stable...
Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is...
<p>Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are prese...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the ...
BACKGROUND: Ranolazine, a piperazine derivative, reduces ischemia via inhibition of the late phase o...
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the ...
International audienceIschemic heart disease is a significant public health problem with high mortal...
This editorial refers to ‘Further insights into the under-lying electrophysiological mechanisms for ...
Introduction: Atrial fibrillation (AF) is a frequent occurrence with advancing age and is associated...
Major steps have been made in the treatment of ischemic heart disease from the discovery of nitrates...
Aims: Ranolazine is an antiischemic and antianginal agent, but experimental and preclinical data pro...
Ranolazine is a piperazine derivative approved as an antianginal. Primarily used as a second-line an...
Adriano AM Truffa, L Kristin Newby, Chiara MelloniDuke Clinical Research Institute and Department of...
Ranolazine derives from piperazine and has been approved as a drug for the therapy of chronic stable...
Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is...
<p>Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are prese...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the ...
BACKGROUND: Ranolazine, a piperazine derivative, reduces ischemia via inhibition of the late phase o...
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the ...
International audienceIschemic heart disease is a significant public health problem with high mortal...
This editorial refers to ‘Further insights into the under-lying electrophysiological mechanisms for ...
Introduction: Atrial fibrillation (AF) is a frequent occurrence with advancing age and is associated...
Major steps have been made in the treatment of ischemic heart disease from the discovery of nitrates...
Aims: Ranolazine is an antiischemic and antianginal agent, but experimental and preclinical data pro...
Ranolazine is a piperazine derivative approved as an antianginal. Primarily used as a second-line an...
Adriano AM Truffa, L Kristin Newby, Chiara MelloniDuke Clinical Research Institute and Department of...
Ranolazine derives from piperazine and has been approved as a drug for the therapy of chronic stable...
Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is...
<p>Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are prese...